IP Library Granted Patent US 8,883,838
Granted Patent B2
US 8,883,838 · App. 13/309,403 · Granted Nov 11, 2014

Pharmaceutical cream compositions and methods of use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,883,838
App. No.
13/309,403
Granted
Nov 11, 2014
Kind
B2
Abstract

The present invention provides pharmaceutical cream compositions comprising oxymetazoline and methods for treating rosacea and other skin disorders as described herein using the above cream compositions.

Claims (25)

1. A pharmaceutical composition comprising:

about 0.0075% to about 2% by weight of oxymetazoline;

about 1% to about 50% by weight of an emollient comprising medium chain triglycerides, diisopropyl adipate, oleyl alcohol and lanolin;

about 8% to about 25% by weight of an emulsifier comprising: cetostearyl alcohol, about 7% to about 10% by weight of PEG-6 stearate/PEG-32 stearate/glycol stearate mixture, macrogol (6) cetostearyl ether, and macrogol (25) cetostearyl ether; wherein the composition is a cream.

2. The pharmaceutical composition of claim 1 , having an emulsifier to emollient ratio of from about 0.7:1 to about 1.8:1.

3. The pharmaceutical composition of claim 1 , further comprising an additive selected from the group consisting of preservatives, emulsion stabilizers, pH adjusters, chelating agents, viscosity modifiers, anti-oxidants, opacifying agents, skin conditioners, buffers, and combinations thereof.

4. The pharmaceutical composition of claim 1 , wherein the composition further comprises a topically active pharmaceutical agent selected from the group consisting of an antimycobacterial agent, an anti-rosacea agent, and a mixture thereof.

5. The pharmaceutical composition of claim 1 , wherein the composition has a pH from about 2.0 to about 7.0 at room temperature.

6. The pharmaceutical composition of claim 1 , wherein the pH is unchanged after about 4 weeks storage at about 25° C./60% RH, about 30° C./75% RH or about 40° C./75% RH.

7. The pharmaceutical composition of claim 1 , wherein the pH is unchanged after about 1 week storage at about 60° C.

8. The pharmaceutical composition of claim 1 , further comprising a vasoconstrictor.

9. The pharmaceutical composition of claim 1 , further comprising one or more components selected from:

one or more preservatives in an amount of from about 0.01% to about 5% by weight of the pharmaceutical composition;

one or more chelating agents in an amount of about 0.001% to about 2% by weight of the pharmaceutical composition;

one or more viscosity modifiers in an amount of from about 0.5% to about 30% by weight of the pharmaceutical composition;

one or more antioxidants in an amount of from about 0.01% to about 3% by weight of the pharmaceutical composition;

one or more opacifying agents in an amount of from about 0.01% to about 20% by weight of the pharmaceutical composition;

one or more skin conditioners in an amount of from about 1% to about 50% by weight of the pharmaceutical composition;

one or more pH regulators in an amount sufficient to provide a pH of from about 2.5 to about 7.0 for the pharmaceutical composition; and combinations thereof.

10. The pharmaceutical composition of claim 1 , which is physically and chemically stable.

11. The pharmaceutical composition of claim 1 , wherein the emollient comprises about 7% by weight of medium chain triglycerides, about 7% by weight of diisopropyl adipate, about 7% by weight of oleyl alcohol and about 2% by weight of lanolin.

12. The pharmaceutical composition of claim 1 , which comprises about 2% by weight of macrogol (6) cetostearyl ether and about 2% by weight of macrogol (25) cetostearyl ether.

13. The pharmaceutical composition of claim 1 , which comprises about 7% to about 8% by weight of PEG-6 stearate/PEG-32 stearate/glycol stearate mixture.

14. The pharmaceutical composition of claim 1 , which comprises about 4% to about 8% by weight of cetostearyl alcohol.

15. The pharmaceutical composition of claim 1 , further comprising 0.01% to about 5% by weight of a preservative comprising methylparaben, propylparaben, and phenoxyethanol.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jan 11, 2023
From: EVENING POST GROUP, LLC
To: EPI HEALTH, LLC
Reel/Frame 062347/0129 →
SECURITY INTEREST Recorded Mar 14, 2022
From: EPI HEALTH, LLC
To: EVENING POST GROUP, LLC
Reel/Frame 059364/0509 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 1, 2019
From: ACLARIS THERAPEUTICS, INC.
To: EPI HEALTH, LLC
Reel/Frame 050905/0290 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2018
From: ALLERGAN, INC.
To: ACLARIS THERAPEUTICS, INC.
Reel/Frame 047681/0466 →